This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alnylam Focuses on Pipeline Development Amid Competition
by Zacks Equity Research
Alnylam (ALNY) is on track with the development of its pipeline despite stiffening competition.
Alnylam Begins Phase III Study on Onpattro for New Indication
by Zacks Equity Research
Alnylam (ALNY) starts phase III APOLLO-B study on its lead drug Onpattro for treating transthyretin amyloidosis with cardiomyopathy. Shares rise.
Company News For Sep 4, 2019
by Zacks Equity Research
Companies in the news are: CONN, MDCO, EBS and RCL
Medicines Company's Inclisiran Succeeds in Pivotal Study
by Zacks Equity Research
The Medicines Company's (MDCO) PCSK9 inhibitor, inclisiran, meets primary endpoint of LDL-C reduction in a pivotal study. Shares up.
Why Is Medicines Co. (MDCO) Down 1.2% Since Last Earnings Report?
by Zacks Equity Research
Medicines Co. (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are Options Traders Betting on a Big Move in Medicines Company (MDCO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.
Alnylam's (ALNY) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Alnylam (ALNY) incurs wider-than-expected loss and misses sales estimates in the second quarter of 2019.
Is a Beat in Store for Melinta (MLNT) This Earnings Season?
by Zacks Equity Research
Vabomere and Minocin are expected to drive Melinta's (MLNT) second-quarter revenues. Operating expenses are likely to be lower. The company may provide update on progress of Baxdela label expansion.
Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View
by Zacks Equity Research
The Medicines Company (MDCO) posts narrower-than-expected loss in Q2. The company did not generate any revenues in the period while its focus is steady on its sole pipeline candidate, inclisiran.
Medicines Co. (MDCO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Medicines Co. (MDCO) delivered earnings and revenue surprises of 4.55% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Melinta (MLNT) Announces Preliminary Product Sales for Q2
by Zacks Equity Research
Melinta (MLNT) announces preliminary sales for the second quarter. However, sales number suggests estimates miss for the quarter. Shares fall.
Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran
by Zacks Equity Research
Alnylam (ALNY) submits Marketing Authorization Application to the EMA for givosiran in development for the treatment of acute hepatic porphyria.
Alnylam Completes Enrollment in Phase III Study of Lumasiran
by Zacks Equity Research
Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1.
Alnylam Completes Rolling NDA Submission to FDA for Givosiran
by Zacks Equity Research
Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.
Options Traders Expect Huge Moves in Medicines Company (MDCO) Stock
by Zacks Equity Research
Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.
Alnylam Initiates Phase I Study on Hypertension Candidate
by Zacks Equity Research
Alnylam (ALNY) initiates phase I study on ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen for the treatment of hypertension in high unmet need populations.
Medicines Co. (MDCO) Up 17.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Medicines Co. (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Alnylam (ALNY) reports narrower-than-expected loss in the first quarter of 2019. Also, sales beat estimates.
Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus
by Zacks Equity Research
The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.
Medicines Co. (MDCO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Medicines Co. (MDCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
by Zacks Equity Research
Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on the same.
Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran
by Zacks Equity Research
Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic porphyria.
Implied Volatility Surging for Medicines Company (MDCO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.
Medicines Co. (MDCO) Up 12.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Medicines Co. (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam's (ALNY) Impressive Pipeline Drives Share Price
by Zacks Equity Research
Alnylam's (ALNY) share price increases on robust performance of pipeline candidates.